• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

    2/27/24 10:33:04 AM ET
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IPA alert in real time by email
    SC 13G 1 ipa13gingsfeb2024.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. )* IMMUNOPRECISE ANTIBODIES LTD. ----------------------------------------------------- (Name of Issuer) COMMON STOCK ----------------------------------------------------- (Title of Class of Securities) 45257F200 ----------------------------------------------------- (CUSIP Number) 02/13/2024 ----------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [] Rule 13d-1(b) [X] Rule 13d-1(c) [] Rule 13d-1(d) ---------- *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 45257F200 -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON(S) I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) INGALLS & SNYDER LLC 135156620 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION UNITED STATES OF AMERICA -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER EACH 1,317,819 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER WITH 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 1,317,819 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,317,819 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.01% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON* ENTITY -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: IMMUNOPRECISE ANTIBODIES LTD -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 3204-4464 Markham St. Victoria, BC V8Z 7X8 Canada -------------------------------------------------------------- Item 2. (a) Name of Person Filing: CHRISTIAN C PARK -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: 1325 AVENUE OF THE AMERICAS, NEW YORK, NY 10019 C/O INGALLS AND SNYDER, LLC -------------------------------------------------------------- (c) Citizenship: USA -------------------------------------------------------------- (d) Title of Class of Securities: COMMON STOCK -------------------------------------------------------------- (e) CUSIP Number: 45257F200 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Rules 240.13d-(1), or 13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or Dealer registered under Section 15 of the Act, (15 U.S.C 78o) (b) [ ] Bank as defined in Section 3(a)(6) of the Act, (15 U.S.C 78c) (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act, (15 U.S.C 78c) (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8) (e) [X] Investment Adviser in accordance with Section 240.13d-1(b)(1)(ii)(E) (f) [ ] Employee Benefit Plan or endowment fund in accordance to Section 240.13d-1(b)(ii)(F) (g) [ ] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G) (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C 1813) (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C 80a-3) (j) [ ] Group, in accordance with Section 240.13d-1(b)(1)(ii)(J) Item 4. Ownership. (a) Amount beneficially owned: 1,317,819 (b) Percent of class: 5.01% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote 1,317,819 (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of 1,317,819 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following []. INAPPLICABLE Item 6. Ownership of More Than Five Percent on Behalf of Another Person. The Shares reported herein are not limited to, but include those of the personal accounts of William McHale, an advisor representative of the Reporting Person. All of the individuals are advisory clients of the Reporting Person. Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. INAPPLICABLE Item 8. Identification and Classification of Members of the Group. INAPPLICABLE Item 9. Notice of Dissolution of Group. INAPPLICABLE Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: 02/27/2024 BY: /s/ CHRISTIAN C PARK ---------------------------------- (Signature)* INGALLS & SNYDER LLC
    Get the next $IPA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IPA

    DatePrice TargetRatingAnalyst
    12/2/2022$9.00Buy
    H.C. Wainwright
    10/25/2021$12.00Buy
    Benchmark
    10/25/2021$12.00Buy
    The Benchmark Company
    More analyst ratings

    $IPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a Bio-Native AI pioneer operating where TechBio meets true biological intelligence, today announced results of a newly expanded study demonstrating that its LENSai™ Immunogenicity Screening can reliably predict Anti-Drug-Antibody (ADA) risk for therapeutic proteins before they enter animal studies or human trials. "ADA-related failures still derail up to 40 percent of biologics in late development, costing companies billions of dollars," said Dr. Jennifer Bath, President & CEO, IPA. "With LENSai, we can now triage candidates against clinical data in hours, not months, giving drug-developers a fast, objective way to de-ri

      7/24/25 8:22:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has serve

      7/21/25 8:28:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live confere

      7/16/25 8:05:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Leadership Updates

    Live Leadership Updates

    See more
    • ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced the appointment of Jeff Fried to its Advisory Board. A recognized leader in healthcare data infrastructure and AI innovation, Jeff Fried brings more than 25 years of experience designing and delivering high-performance data for complex life sciences and clinical environments. He currently serves as Director of Platform Strategy and Innovations for InterSystems, where he helps shape high-performance data solutions for some of the world's most demanding healthcare and life sciences environments. He has serve

      7/21/25 8:28:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

      ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced the appointment of Jon Lieber to its Board of Directors, effective immediately. Mr. Lieber brings over 30 years of financial and strategic leadership across the biotechnology and life sciences sectors, with deep expertise in capital markets, investor relations, and corporate development. He currently serves as Chief Financial Officer at Rallybio, a clinical-stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded

      7/7/25 9:00:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies Announces Key Leadership Changes

      ImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250224016053/en/Kamil Isaev (Photo: Business Wire) Kamil Isaev Joins IPA's Board of Directors IPA is pleased to welcome Dr. Isaev, a seasoned technology leader and venture strategist, to its

      2/24/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    SEC Filings

    See more
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/24/25 9:40:10 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/21/25 9:50:55 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by ImmunoPrecise Antibodies Ltd.

      6-K - ImmunoPrecise Antibodies Ltd. (0001715925) (Filer)

      7/14/25 9:31:46 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on ImmunoPrecise Antibodies with a new price target

      H.C. Wainwright initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $9.00

      12/2/22 8:15:24 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on ImmunoPrecise Antibodies with a new price target

      Benchmark initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:31:59 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • The Benchmark Company initiated coverage on ImmunoPrecise Antibodies with a new price target

      The Benchmark Company initiated coverage of ImmunoPrecise Antibodies with a rating of Buy and set a new price target of $12.00

      10/25/21 7:28:32 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Financials

    Live finance-specific insights

    See more
    • IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for fourth quarter and full fiscal year end 2025, on Tuesday, July 29, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. ImmunoPrecise management will host the conference call followed by a question-and-answer period. Conference Call and Webcast Details The Company will host a live confere

      7/16/25 8:05:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

      Secures $8-$10M Strategic Partnership Scales AI Infrastructure Collaborations with Vultr and Leading Providers of Advanced GPU technologies to Accelerate de novo Drug Discovery. Unlocking Margin Expansion Through Scalable AI IPA Strengthens Board & Management Team Kamil Isaev, Joseph Scheffler, and Dr. Li Hui join IPA, enhancing leadership in AI, finance, and client relations. IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today reported financial results for the third quarter ("Q3") of its 2025 fiscal year ("FY25"), which ended January 31, 2025. "As we continue to revolutionize the AI-enabled drug disc

      3/28/25 8:01:00 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

      The Company to host an earnings conference call via webcast ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and development, today announces the rescheduling of its Third Quarter Fiscal 2025 financial results and business highlights release. Originally set for March 13, 2025, the new release date is Friday, March 28, 2025, and IPA will hold an earnings call at 10:30 am Eastern Time the same day. The Company is providing additional time to allow its auditors to complete the necessary reviews and audit requirements on valuation calculations of goodwill and intangible assets. This extension ensures that the financial data

      3/11/25 10:17:00 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

      SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      2/27/24 10:33:04 AM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ImmunoPrecise Antibodies Ltd. (Amendment)

      SC 13G/A - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      1/10/24 1:53:08 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ImmunoPrecise Antibodies Ltd.

      SC 13G - ImmunoPrecise Antibodies Ltd. (0001715925) (Subject)

      1/10/24 1:33:21 PM ET
      $IPA
      Biotechnology: Pharmaceutical Preparations
      Health Care